Drug Profile
LY 3415244
Alternative Names: LY3415244Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company (India) Pvt. Ltd
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action HAVCR2 protein inhibitors; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Belgium (IV)
- 28 Dec 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Japan (IV)
- 28 Dec 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV)